AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31630072 — intervention group
Group type: EXPERIMENTAL
Intervention: No communication contact
Number of subjects: 146
Study 29320575 — intervention group
Group type: EXPERIMENTAL
Intervention: AZP-531 (3 mg for 50-70 kg and 4 mg for >70 kg body weight)
Number of subjects: 47
Study 29320575 — intervention group
Group type: EXPERIMENTAL
Intervention: AZP-531
Number of subjects: 47
Study 29320575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 27552643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell voltage (CV-LVH)
Number of subjects: 3043
Study 27552643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell product (CP-LVH)
Number of subjects: 3043
Study 27552643 — intervention group
Group type: COMPARATOR
Intervention: Sokolow-Lyon-LVH
Number of subjects: 3043
Study 27552643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell voltage and Cornell product criteria for LVH
Number of subjects: 3043
Study 27552643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell product
Number of subjects: 3043
Study 25099397 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Number of subjects: 433
Study 25099397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433
Study 23045301 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide
Number of subjects: 562
Study 23045301 — intervention group
Group type: COMPARATOR
Intervention: iodixanol
Number of subjects: 562
Study 19665142 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (200 mg/d)
Number of subjects: 55
Study 19665142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 18606587 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin once daily (5 mg/kg/die)
Number of subjects: 21
Study 18606587 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin twice daily (5 mg/kg/die)
Number of subjects: 21
Study 15681986 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation breathing exercise (30 minutes daily for 6 weeks)
Number of subjects: 35
Study 15681986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 35
Study 15681986 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation breathing exercise
Number of subjects: 35
Study 15681986 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 11996638 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 11996638 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 10450626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 632
Study 10450626 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 632
Study 7541051 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE after radical resection
Number of subjects: 140
Study 7541051 — intervention group
Group type: COMPARATOR
Intervention: Radical resection only
Number of subjects: 140
Study 7541051 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE after palliative hepatectomy
Number of subjects: 140
Study 7541051 — intervention group
Group type: COMPARATOR
Intervention: Palliative resection only
Number of subjects: 140
Study 1982330 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms) + procaterol
Number of subjects: 24
Study 1982330 — intervention group
Group type: COMPARATOR
Intervention: Theophylline + procaterol
Number of subjects: 24
Study 42425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg/70 kg
Number of subjects: 0
Study 42425 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 0
Study 31888707 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Treatment (iCBT) added to treatment as usual (TAU)
Number of subjects: 260
Study 31888707 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 260
Study 28291859 — intervention group
Group type: EXPERIMENTAL
Intervention: Two interforaminal Straumann implants (Regular Neck, 4.1 mm diameter, 8 mm length) loaded with Locator attachments transforming preexisting inferior conventional denture into an IOD.
Number of subjects: 19
Study 26296857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.4 g daily for 1 month)
Number of subjects: 80
Study 26296857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23459089 — intervention group
Group type: EXPERIMENTAL
Intervention: MOM trial Handbook plus structured physical activity and nutrition program
Number of subjects: 60
Study 23459089 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 60
Study 21168841 — intervention group
Group type: EXPERIMENTAL
Intervention: SEDASYS System (SED)
Number of subjects: 1000
Study 21168841 — intervention group
Group type: COMPARATOR
Intervention: Control standard care (CSC)
Number of subjects: 1000
Study 19489491 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion on Guanyuan (CV 4), Qihai (CV 6), Zusanli (ST 36), Xuehai (SP 10), Geshu (BL 17)
Number of subjects: 80
Study 19489491 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Omeprazole and Amoxicillin)
Number of subjects: 80
Study 19489491 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 80
Study 17196876 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 100
Study 16261464 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (loading dose of 125 microg kg(‐1) min(‐1) for 1 min followed by an infusion at 40 microg kg(‐1) min(‐1) for 4 min)
Number of subjects: 22
Study 16261464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11555220 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribing training intervention for primary health care nurses
Number of subjects: 457
Study 11555220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 457
Study 9260344 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 21
Study 9260344 — intervention group
Group type: COMPARATOR
Intervention: No-treatment wait‐list control
Number of subjects: 21
Study 8372340 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/d)
Number of subjects: 17
Study 8372340 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg/d)
Number of subjects: 17
Study 3553281 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine 10 mg three times a day for 30 days, then 5 mg three times a day for 60 days
Number of subjects: 42
Study 3553281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 2537605 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP alone
Number of subjects: 51
Study 2537605 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP-CQ
Number of subjects: 51
Study 2537605 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP-etoposide
Number of subjects: 51
Study 31475496 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoshen Zhitong needling
Number of subjects: 80
Study 31475496 — intervention group
Group type: COMPARATOR
Intervention: Routine needling
Number of subjects: 80
Study 27748006 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1358
Study 27748006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1358
Study 25972286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin 200 mg
Number of subjects: 36
Study 25972286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22486331 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire thinking induction
Number of subjects: 45
Study 22486331 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 45
Study 22486331 — intervention group
Group type: COMPARATOR
Intervention: Verbal reasoning
Number of subjects: 45
Study 22191245 — intervention group
Group type: EXPERIMENTAL
Intervention: Vena cava filter placement
Number of subjects: 0
Study 22191245 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy alone
Number of subjects: 0
Study 19101237 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 1,000 ml/day of fluid intake, 120 mmol/day sodium, and 250 mg furosemide twice daily
Number of subjects: 410
Study 19101237 — intervention group
Group type: COMPARATOR
Intervention: Group B: 1,000 ml/day of fluid intake, 120 mmol/day sodium, and 125 mg furosemide twice daily
Number of subjects: 410
Study 19101237 — intervention group
Group type: COMPARATOR
Intervention: Group C: 1,000 ml/day fluid intake, 80 mmol/day sodium, and 250 mg furosemide twice daily
Number of subjects: 410
Study 19101237 — intervention group
Group type: COMPARATOR
Intervention: Group D: 1,000 ml/day fluid intake, 80 mmol/day sodium, and 125 mg furosemide twice daily
Number of subjects: 410
Study 19101237 — intervention group
Group type: COMPARATOR
Intervention: Group E: 2,000 ml/day fluid intake, 120 mmol/day sodium, and 250 mg furosemide twice daily
Number of subjects: 410
Study 19101237 — intervention group
Group type: COMPARATOR
Intervention: Group F: 2,000 ml/day fluid intake, 120 mmol/day sodium, and 125 mg furosemide twice daily
Number of subjects: 410
Study 19101237 — intervention group
Group type: COMPARATOR
Intervention: Group G: 2,000 ml/day fluid intake, 80 mmol/day sodium, and 250 mg furosemide twice daily
Number of subjects: 410
Study 19101237 — intervention group
Group type: COMPARATOR
Intervention: Group H: 2,000 ml/day fluid intake, 80 mmol/day sodium, and 125 mg furosemide twice daily
Number of subjects: 410
Study 16216019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 619
Study 16216019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 15331895 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg intravenous Ketorolac
Number of subjects: 24
Study 15331895 — intervention group
Group type: COMPARATOR
Intervention: No analgesia (Control)
Number of subjects: 24
Study 11098157 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal angle for force development (Lo)
Number of subjects: 24
Study 11098157 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow flexion with forearm in midrange position
Number of subjects: 24
Study 9117306 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (46 Gy 5 days per week in 30‐38 days)
Number of subjects: 172
Study 9117306 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 172
Study 7691114 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 59
Study 7691114 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF + quinolone
Number of subjects: 59
Study 3456148 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlipid supplementation (7% of total calories) for 1 year
Number of subjects: 13
Study 3456148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Microlipid supplementation)
Number of subjects: 13
Study 29624664 — intervention group
Group type: EXPERIMENTAL
Intervention: Mein Weg (trauma-focused group intervention)
Number of subjects: 99
Study 29624664 — intervention group
Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 99
Study 28339596 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic health warning (GHW)
Number of subjects: 142
Study 28339596 — intervention group
Group type: COMPARATOR
Intervention: Text-only warning
Number of subjects: 142
Study 26322721 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment script that explicitly requested non-registered donors
Number of subjects: 0
Study 26322721 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation induction (morally inspiring story)
Number of subjects: 0
Study 26322721 — intervention group
Group type: COMPARATOR
Intervention: Recruitment script that did not list eligibility requirements
Number of subjects: 0
Study 23000049 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented group (1ml Vertecem V+ injected in each screw hole before screw positioning)
Number of subjects: 12
Study 23000049 — intervention group
Group type: COMPARATOR
Intervention: Non-augmented group (fixed using LCP DF without augmentation)
Number of subjects: 12
Study 21180677 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% hyaluronan-containing mouthwash
Number of subjects: 45
Study 21180677 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 45
Study 21180677 — intervention group
Group type: COMPARATOR
Intervention: Water-based mouthwash (negative control)
Number of subjects: 45
Study 21180677 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro effects on bacteria
Number of subjects: 45
Study 18211656 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured pharmaceutical care service (including education and introduction of intensive self‐monitoring)
Number of subjects: 165
Study 18211656 — intervention group
Group type: COMPARATOR
Intervention: Traditional services
Number of subjects: 165
Study 16322118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (50 mg daily) and methotrexate (2.5 mg twice daily on days 1 and 4)
Number of subjects: 171
Study 16322118 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide (50 mg daily) and methotrexate (2.5 mg twice daily on days 1 and 4) plus thalidomide (200 mg daily)
Number of subjects: 171
Study 12560954 — intervention group
Group type: COMPARATOR
Intervention: Weightlifters (WL)
Number of subjects: 20
Study 12560954 — intervention group
Group type: COMPARATOR
Intervention: Powerlifters (PL)
Number of subjects: 20
Study 12560954 — intervention group
Group type: COMPARATOR
Intervention: Sprinters (S)
Number of subjects: 20
Study 12560954 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-athletes (NA)
Number of subjects: 20
Study 10098569 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin‐Primaquine (CP)
Number of subjects: 145
Study 10098569 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim‐Sulfamethoxazole (TS)
Number of subjects: 145
Study 10098569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone‐Trimethoprim (DT)
Number of subjects: 145
Study 7566230 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of children with Down's syndrome
Number of subjects: 110
Study 7566230 — intervention group
Group type: COMPARATOR
Intervention: Control parents
Number of subjects: 110
Study 1704880 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 7340274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin-clindamycin
Number of subjects: 47
Study 7340274 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin followed by cephalexin
Number of subjects: 47
Study 31468237 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal muscle vibration (fMV)
Number of subjects: 0
Study 31468237 — intervention group
Group type: COMPARATOR
Intervention: Whole body vibration (WBV)
Number of subjects: 0
Study 29020479 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silicone gel applied after Er:YAG laser treatment
Number of subjects: 19
Study 29020479 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied after Er:YAG laser treatment
Number of subjects: 19
Study 26923831 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intranasal splints removed on the fifth postoperative day
Number of subjects: 0
Study 26923831 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intranasal splints removed on the seventh postoperative day
Number of subjects: 0
Study 26923831 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intranasal splints removed on the tenth postoperative day
Number of subjects: 0
Study 24786930 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive home exercise (12 weeks, 5 days/week) followed by twice-a-week home or gym exercise (12 weeks)
Number of subjects: 19
Study 24786930 — intervention group
Group type: COMPARATOR
Intervention: Range of motion exercise (24 weeks, 5 days/week)
Number of subjects: 19
Study 22402568 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP/INSURE
Number of subjects: 256
Study 22402568 — intervention group
Group type: COMPARATOR
Intervention: Oxygen/MV
Number of subjects: 256
Study 20465148 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental intervention to alter school environment for healthier eating and physical activity (18 months)
Number of subjects: 77
Study 19101898 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine nuclear matrix protein 22 (NMP22) measurement
Number of subjects: 151
Study 19101898 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants without TCC)
Number of subjects: 151
Study 19101898 — intervention group
Group type: EXPERIMENTAL
Intervention: NMP22 for detecting stage Ta tumors
Number of subjects: 151
Study 19101898 — intervention group
Group type: EXPERIMENTAL
Intervention: NMP22 for detecting grade 1 tumors
Number of subjects: 151
Study 15674301 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based meal replacement (MR)
Number of subjects: 104
Study 15674301 — intervention group
Group type: COMPARATOR
Intervention: Individualized diet plan (IDP)
Number of subjects: 104
Study 11837933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 47
Study 11837933 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 47
Study 9840102 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glucocorticosteroids (hydrocortisone acetate foam preparation, 100 mg b.i.d.)
Number of subjects: 19
Study 9840102 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without intestinal inflammation)
Number of subjects: 19
Study 8134189 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk (with native lactoferrin)
Number of subjects: 8
Study 8134189 — intervention group
Group type: COMPARATOR
Intervention: Lactoferrin-free breast milk
Number of subjects: 8
Study 2673795 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF 1194
Number of subjects: 21
Study 2673795 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 21
Study 2673795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1091216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluprednylidene acetate cream applied once daily plus cream base of the same formulation twice daily
Number of subjects: 31
Study 1091216 — intervention group
Group type: COMPARATOR
Intervention: Fluprednylidene acetate cream applied 3 times daily
Number of subjects: 31
Study 1091216 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 17-valerate cream applied 3 times daily
Number of subjects: 31
Study 31037773 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment group
Number of subjects: 0
Study 31037773 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 29226134 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine (BD)
Number of subjects: 29
Study 29226134 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA‐Plus (MTA‐P)
Number of subjects: 29
Study 29226134 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA (PR‐MTA)
Number of subjects: 29
Study 29226134 — intervention group
Group type: COMPARATOR
Intervention: Ferric sulfate (FS)
Number of subjects: 29
Study 26107852 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency-based training intervention for DSPs
Number of subjects: 0
Study 26107852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 0
Study 23563444 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of daily patching with active vision therapy
Number of subjects: 19
Study 23563444 — intervention group
Group type: COMPARATOR
Intervention: 2 hours of daily patching with placebo vision therapy
Number of subjects: 19
Study 21042047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task (DT) group (stepping exercise in DT conditions, n=26)
Number of subjects: 53
Study 21042047 — intervention group
Group type: COMPARATOR
Intervention: Single-task (ST) group (stepping exercise in ST conditions, n=27)
Number of subjects: 53
Study 19500724 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-ended question without social desirability bias
Number of subjects: 312
Study 19500724 — intervention group
Group type: COMPARATOR
Intervention: Closed-ended question without social desirability bias
Number of subjects: 312
Study 19500724 — intervention group
Group type: COMPARATOR
Intervention: Open-ended question with social desirability bias
Number of subjects: 312
Study 19500724 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up questions for all groups
Number of subjects: 312
Study 16751018 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 19
Study 16751018 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 15559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor-based first line triple therapies
Number of subjects: 25644
Study 15559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate based regimens
Number of subjects: 25644
Study 15559530 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 blockers-based therapies
Number of subjects: 25644
Study 15559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor-based double combinations
Number of subjects: 25644
Study 15559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin+amoxicillin/nitroimidazole combinations
Number of subjects: 25644
Study 15559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-nitroimidazole regimens
Number of subjects: 25644
Study 15559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line triple regimens
Number of subjects: 25644
Study 15559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapies (first-line)
Number of subjects: 25644
Study 15559530 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapies (second-line)
Number of subjects: 25644
Study 11426363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (30,000 KIU/kg added to pump prime, 15,000 KIU/kg every hour during cardiopulmonary bypass)
Number of subjects: 60
Study 11426363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver system (used to collect all blood at the operation site)
Number of subjects: 60